Acrivon Therapeutics, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
23.13
|
|
Average Rating
|
4.50
|
|
# Strong Buys
|
5
|
|
# Buys
|
5
|
|
# Holds
|
0
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2024-09-30
|
-0.59
|
-0.59
|
0.00
|
0.24%
|
|
2024-06-30
|
-0.57
|
-0.52
|
0.05
|
8.77%
|
|
2024-03-31
|
-0.84
|
-0.73
|
0.11
|
13.10%
|
|
2023-12-31
|
-0.73
|
-0.86
|
-0.13
|
-17.81%
|
|
2023-09-30
|
-0.71
|
-0.66
|
0.05
|
7.04%
|
|
2023-06-30
|
-0.65
|
-0.63
|
0.02
|
3.08%
|
|
2023-03-31
|
-0.60
|
-0.58
|
0.02
|
3.33%
|
|
2022-12-31
|
-1.09
|
-0.80
|
0.29
|
26.61%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2024-09-30
|
-1.84
|
|
2023-12-31
|
-2.73
|
|
2022-12-31
|
-1.31
|